Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Current Leases (2024 - 2025)

Prelude Therapeutics' Current Leases history spans 2 years, with the latest figure at $2.7 million for Q4 2025.

  • For Q4 2025, Current Leases rose 1219.23% year-over-year to $2.7 million; the TTM value through Dec 2025 reached $2.7 million, up 1219.23%, while the annual FY2025 figure was $2.7 million, 1219.23% up from the prior year.
  • Current Leases for Q4 2025 was $2.7 million at Prelude Therapeutics, up from $208000.0 in the prior quarter.
  • Across five years, Current Leases topped out at $2.7 million in Q4 2025 and bottomed at $208000.0 in Q4 2024.